<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0"><channel><title>Individual feed for https://seekingalpha.com/feed.xml</title><link>https://seekingalpha.com/feed.xml</link><description>Individual feed output.</description><lastBuildDate>Sat, 06 Dec 2025 02:12:40 GMT</lastBuildDate><generator>PyRSS2Gen-1.1.0</generator><docs>http://blogs.law.harvard.edu/tech/rss</docs><item><title>Swiss Water: Premium Process, Questionable Moat And A Shaky Coffee Market</title><link>https://seekingalpha.com/article/4850885-swiss-water-premium-process-questionable-moat-and-a-shaky-coffee-market?source=feed_all_articles</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture6.png</image_url><description></description><pubDate>Sat, 06 Dec 2025 07:07:52 GMT</pubDate></item><item><title>Lock 8% By Horizon Technology Finance's Baby Bonds For Your Ladder Portfolio</title><link>https://seekingalpha.com/article/4850884-lock-8-percent-by-horizon-technology-finance-baby-bonds-ladder-portfolio?source=feed_all_articles</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture8.png</image_url><description></description><pubDate>Sat, 06 Dec 2025 06:47:28 GMT</pubDate></item><item><title>CVS: FY 2026 Margin Recovery, Well Covered Dividends, And Cheap Valuations</title><link>https://seekingalpha.com/article/4850883-cvs-fy2026-margin-recovery-well-covered-dividends-and-cheap-valuations?source=feed_all_articles</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture6.png</image_url><description></description><pubDate>Sat, 06 Dec 2025 06:38:16 GMT</pubDate></item><item><title>Why An Investment Process Matters, Especially In Volatile Markets</title><link>https://seekingalpha.com/article/4850886-investment-process-matters-especially-volatile-markets?source=feed_all_articles</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture6.png</image_url><description></description><pubDate>Sat, 06 Dec 2025 06:25:00 GMT</pubDate></item><item><title>Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript</title><link>https://seekingalpha.com/article/4850828-capricor-therapeutics-inc-capr-discusses-hopeminus-3-phase-iii-top-line-data-for-deramiocel?source=feed_all_articles</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture10.png</image_url><description></description><pubDate>Sat, 06 Dec 2025 06:18:57 GMT</pubDate></item></channel></rss>